Naturally Splendid Enterprises Ltd. (“Naturally Splendid” or “NSE” or “The Company”) (TSXV:NSP) (OTCQB:NSPDF) (Frankfurt:50N) is pleased to announce it has received a purchase order from Pure Integrative Pharmacy for NATERAFX™.

NATERA FX™ will now be available at all 15 Pure Integrative Pharmacy locations; 14 in Greater Vancouver and one in Courtenay, B.C.


Dr. Swetlikoff, Lead Medical Advisor for NATERA FX™ and Advisory Board Member of Naturally Splendid states, “We are pleased to have secured our first pharmacy chain as clients of NATERA FX™. Although many practitioners carry an inventory of products for clients, there are also those who choose not to and refer their patients to pharmacies. In this regard, Pure Integrative Pharmacies will serve as a dispensary for NATERA FX products. Furthermore, pharmacists that have access to NATERA FX™ will also be able to recommend the products directly to their customers. We look forward to adding additional pharmacy chains to provide wide access to NATERA FX™ products”.

NATERA FX™ products are marketed directly to health care professionals, including but not limited to, Naturopathic Doctors, Doctors of Chiropractic, Medical Doctors and Pharmacies via a nationwide network of Medical Advisors and Consultants as well as an e-Commerce website.

Additional Natural Product Numbers (NPNs):
NATERA FX™ currently has five products that have received Natural Product Numbers (NPNs) from Health Canada. They are as follows:

  • LEAN FX Body Composition Formula (619g) NPN: 80087708
  • MATRIX Bone & Joint Formula (90C) NPN: 80089215
  • MVP Multivitamin & Phytonutrient Formula (120C) NPN: 80085246
  • PHYTO MOOD Mood Imbalance & Sleep Aid (90C) NPN: 80084609
  • RELIEF Anti-Inflammatory Formula (60C) NPN: 80082780

Appointed to the NATERA FX Medical Team as Medical Consultant

Dr. Laura Stix, BSc (Hons) ND
Dr. Stix is a licensed Naturopathic Doctor (Boucher Institute of Naturopathic Medicine, New Westminster, BC) with an Honours Degree in Science from the University of Waterloo, ON, graduating magna cum laude with a Major in Psychology and a Minor in Biology. Awarded a research grant to study the brain, her interests ultimately led to mind-body medicine, completing advanced training in hypnotherapy and neuro-linguistic programming.

Dr. Stix practices in Waterloo, ON, and has joined the NATERA FX™ team as a Medical Consultant to health care professionals in Ontario where she directly consults with multiple disciplines – including Naturopathic Doctors, Doctors of Chiropractic, Medical Doctors, Pharmacists, and others – to guide them in recommending the most effective application of the NATERAFX™ professional line of natural health products for their clients. With a decade of clinical experience, her practice is centered on lifestyle medicine and evidence-based therapies.

For more information on NATERA FX™, please visit their website: www.naterafx.com

About Naturally Splendid Enterprises Ltd.

Naturally Splendid is a biotechnology and consumer products company that is developing, producing, commercializing, and licensing an entirely new generation of plant-derived, bioactive ingredients, nutrient dense foods, and related products. Naturally Splendid is building an expanding portfolio of patents (issued and pending) and proprietary intellectual property focused on the commercial uses of industrial hemp cannabinoid compounds in a broad spectrum of applications.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-673-9573

On Behalf of the Board of Directors
Mr. Douglas Mason
CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.
(NSP – TSX Venture; NSPDF – OTCQB; 50N Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office:  (604) 465-0548
Fax:      (604) 465-1128

E-mail: info@naturallysplendid.com
Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid’s control including, Naturally Splendid’s ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Click here to connect with Naturally Splendid (TSXV:NSP) for an Investor Presentation.

Source: globenewswire.com

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less